Etzer Darout
Stock Analyst at Barclays
(3.58)
# 872
Out of 5,045 analysts
132
Total ratings
46.46%
Success rate
7.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Upgrades: Overweight | $6 → $23 | $14.67 | +56.78% | 7 | Oct 29, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Overweight | $15 → $14 | $8.02 | +74.56% | 7 | Oct 22, 2025 | |
| SMMT Summit Therapeutics | Maintains: Underweight | $13 → $16 | $18.66 | -14.26% | 2 | Oct 21, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $35 → $58 | $29.78 | +94.76% | 2 | Oct 21, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $3.5 → $6 | $3.26 | +84.05% | 12 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Underweight | $25 | $25.99 | -3.81% | 1 | Oct 13, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $61 | $4.78 | +1,176.15% | 1 | Oct 13, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Overweight | $48 | $27.61 | +73.85% | 1 | Oct 13, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $125 | $84.16 | +48.54% | 1 | Oct 13, 2025 | |
| CRVS Corvus Pharmaceuticals | Initiates: Overweight | $16 | $7.68 | +108.33% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $78 | $36.12 | +115.95% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $98.94 | +43.52% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $94.81 | +2.31% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $44 | $29.27 | +50.32% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.51 | +298.41% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.69 | +77.51% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $40 | $39.43 | +1.45% | 4 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $9.59 | +66.84% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $76.69 | -6.12% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $60.03 | -0.05% | 2 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $47 | $27.81 | +69.00% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.16 | +212.50% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $103.35 | +38.36% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $2.68 | +11.94% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.70 | +199.15% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.36 | +2,569.49% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.89 | +1,328.57% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $102.97 | +30.13% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $28.95 | +65.80% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $121.80 | -1.48% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.34 | +347.76% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $82.23 | -0.28% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.23 | +349.17% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $481.59 | -64.70% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.00 | - | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $70.46 | -46.07% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.34 | +2,122.22% | 1 | Mar 28, 2018 |
Xencor
Oct 29, 2025
Upgrades: Overweight
Price Target: $6 → $23
Current: $14.67
Upside: +56.78%
Terns Pharmaceuticals
Oct 22, 2025
Maintains: Overweight
Price Target: $15 → $14
Current: $8.02
Upside: +74.56%
Summit Therapeutics
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $18.66
Upside: -14.26%
RAPT Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $35 → $58
Current: $29.78
Upside: +94.76%
CytomX Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $3.26
Upside: +84.05%
Celldex Therapeutics
Oct 13, 2025
Initiates: Underweight
Price Target: $25
Current: $25.99
Upside: -3.81%
Tvardi Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.78
Upside: +1,176.15%
Oruka Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $27.61
Upside: +73.85%
Monopar Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $84.16
Upside: +48.54%
Corvus Pharmaceuticals
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $7.68
Upside: +108.33%
Oct 13, 2025
Initiates: Overweight
Price Target: $78
Current: $36.12
Upside: +115.95%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $98.94
Upside: +43.52%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $94.81
Upside: +2.31%
Sep 24, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $29.27
Upside: +50.32%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.51
Upside: +298.41%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.69
Upside: +77.51%
Sep 17, 2025
Initiates: Equal-Weight
Price Target: $40
Current: $39.43
Upside: +1.45%
Sep 17, 2025
Assumes: Overweight
Price Target: $16
Current: $9.59
Upside: +66.84%
Sep 17, 2025
Initiates: Overweight
Price Target: $72
Current: $76.69
Upside: -6.12%
Sep 17, 2025
Initiates: Overweight
Price Target: $60
Current: $60.03
Upside: -0.05%
Sep 17, 2025
Initiates: Overweight
Price Target: $47
Current: $27.81
Upside: +69.00%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.16
Upside: +212.50%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $103.35
Upside: +38.36%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.68
Upside: +11.94%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $11.70
Upside: +199.15%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.36
Upside: +2,569.49%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.89
Upside: +1,328.57%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $102.97
Upside: +30.13%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $28.95
Upside: +65.80%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $121.80
Upside: -1.48%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.34
Upside: +347.76%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $82.23
Upside: -0.28%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.23
Upside: +349.17%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $481.59
Upside: -64.70%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.00
Upside: -
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $70.46
Upside: -46.07%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.34
Upside: +2,122.22%